BioStem Technologies Statistics
Want to see BSEM full AI Analyst Report?
BioStem Technologies (BSEM) Stock Statistics & Valuation Metrics
Total Valuation
BioStem Technologies has a market cap or net worth of $20.14M. The enterprise value is $55.39M.
- Market Cap
- $20.14M
- Enterprise Value
- $55.39M
Share Statistics
BioStem Technologies has 19,178,630 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 19,178,630
- Owned by Insiders
- 1.05%
- Owned by Institutions
- 4.52%
Financial Efficiency
BioStem Technologies’s return on equity (ROE) is -0.17 and return on invested capital (ROIC) is -1.62%.
- Return on Equity (ROE)
- -0.17
- Return on Assets (ROA)
- -0.13
- Return on Invested Capital (ROIC)
- -1.62%
- Return on Capital Employed (ROCE)
- -0.02
- Revenue Per Employee
- 650.44K
- Profits Per Employee
- -90.15K
- Employee Count
- 73
- Asset Turnover
- 0.95
- Inventory Turnover
- 1.13
Valuation Ratios
The current PE Ratio of BioStem Technologies is -0.45. BioStem Technologies’s PEG ratio is 0.01.
- PE Ratio
- -0.45
- PS Ratio
- -0.32
- PB Ratio
- 1.02
- Price to FCF
- -1.57
- Price to Operating Cash Flow
- -1.52
- PEG Ratio
- 0.01
Income Statement
In the last 12 months, BioStem Technologies had revenue of 47.48M and earned -6.58M in profits. Earnings per share was -0.39.
- Revenue
- 47.48M
- Gross Profit
- 44.22M
- Operating Income
- -689.15K
- Pretax Income
- -389.65K
- Net Income
- -6.58M
- EBITDA
- -308.13K
- Earnings Per Share (EPS)
- -0.39
Cash Flow
In the last 12 months, operating cash flow was -12.36M and capital expenditures -494,769, giving a free cash flow of -12.85M billion.
- Operating Cash Flow
- -12.36M
- Free Cash Flow
- -12.85M
- Free Cash Flow per Share
- -0.72
Dividends & Yields
BioStem Technologies pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -63.83%
- Earnings Yield
- -215.53%
Stock Price Statistics
- Beta
- 1.88
- 52-Week Price Change
- -74.64%
- 50-Day Moving Average
- 2.58
- 200-Day Moving Average
- 3.92
- Relative Strength Index (RSI)
- 33.55
- Average Volume (3m)
- 182.78K
Important Dates
BioStem Technologies upcoming earnings date is Apr 05, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 12, 2026
- Next Earnings Date
- Apr 05, 2027
- Ex-Dividend Date
- ―
Financial Position
BioStem Technologies as a current ratio of 4.12, with Debt / Equity ratio of 8.51%
- Current Ratio
- 4.12
- Quick Ratio
- 3.85
- Debt to Market Cap
- 0.05
- Net Debt to EBITDA
- 85.09
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, BioStem Technologies has paid 6.19M in taxes.
- Income Tax
- 6.19M
- Effective Tax Rate
- -15.89
Enterprise Valuation
BioStem Technologies EV to EBITDA ratio is -0.60, with an EV/FCF ratio of -1.58.
- EV to Sales
- -0.32
- EV to EBITDA
- -0.60
- EV to Free Cash Flow
- -1.58
- EV to Operating Cash Flow
- -1.65
Balance Sheet
BioStem Technologies has $971.14K in cash and marketable securities with $1.17M in debt, giving a net cash position of -$194.68K billion.
- Cash & Marketable Securities
- $971.14K
- Total Debt
- $1.17M
- Net Cash
- -$194.68K
- Net Cash Per Share
- -$0.01
- Tangible Book Value Per Share
- -$0.23
Margins
Gross margin is 116.59%, with operating margin of 54.74%, and net profit margin of 64.03%.
- Gross Margin
- 116.59%
- Operating Margin
- 54.74%
- Pretax Margin
- 57.78%
- Net Profit Margin
- 64.03%
- EBITDA Margin
- 53.91%
- EBIT Margin
- 57.30%
Analyst Forecast
The average price target for BioStem Technologies is $7.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- $7.00
- Price Target Upside
- 566.67% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 1
- Revenue Growth Forecast
- -86.50%
- EPS Growth Forecast
- -291.62%
Scores
- Smart Score
- ―
- AI Score
- 44

